Paper Details

  1. Home
  2. Paper Details

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

Author: BergmanAndré M, HeijminkStijn Wtpj, Van der RoestRosanne Cv, ZwartWilbert, de JongJeroen, van HoudtPetra J, van der HeideUulke A, van der PoelHenk G

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report presents a patient with high-grade prostate cancer who underwent 3 months of neoadjuvant enzalutamide. This resulted in tumor size reduction, downstaging, and increased ADC value on DWI-MRI sequences. Histological changes were also observed.
Paper Details　
Original Abstract of the Article :
The effects of enzalutamide monotherapy on prostate tumor downsizing and multiparametric MRI are currently unknown. Here we present the first case in literature of a patient with high-grade prostate cancer who underwent 3 months of neoadjuvant enzalutamide, for which the effects on mpMRI and histolo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909636/

データ提供：米国国立医学図書館（NLM）

Enzalutamide: A Promising Neoadjuvant Therapy for Prostate Cancer

Enzalutamide, a medication used for the treatment of prostate cancer, has shown promise as a neoadjuvant therapy. This case report examines the effects of enzalutamide monotherapy on multiparametric 3T MR imaging in a patient with high-grade prostate cancer. The authors assess the impact of enzalutamide on tumor size, multiparametric MRI parameters, and histological changes, providing insights into its potential as a neoadjuvant treatment.

Tumor Shrinking: Enzalutamide's Neoadjuvant Potential

The case report demonstrates tumor size reduction and downstaging after three months of neoadjuvant enzalutamide treatment. The study also observes an increase in ADC value on DWI-MRI sequences, indicating a potential for enzalutamide to alter tumor characteristics.

A New Frontier: Exploring Neoadjuvant Therapies

This case report highlights the potential of enzalutamide as a promising neoadjuvant therapy for prostate cancer. Further research is needed to validate these findings and explore its efficacy in larger patient populations.

Dr. Camel's Conclusion

Just as a camel navigates a challenging desert terrain, we must seek innovative therapies for prostate cancer. This case report suggests that enzalutamide may offer a new path to effective treatment, potentially shrinking tumors and improving outcomes for patients.

Date :
  1. Date Completed 2016-06-23
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

27335799

DOI: Digital Object Identifier

PMC4909636

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.